19 November 2026

Dear Ataxia UK,

Thank you for your request for information regarding Biogen's work to identify a path forward to secure access for people living with Friedreich's ataxia in England.

We recognise that Friedreich's ataxia is a devastating condition and appreciate the profound burdens it places on people living with the disease and their families.

Biogen was disappointed to have to make the decision to withdraw omaveloxolone from the NICE evaluation process in April 2025, as NICE informed Biogen the appraisal would be terminated.

It is Biogen's intention to resubmit to NICE. We are in dialogue with NICE and NHS England and are working together to find a path forward.

Yours sincerely,

Kylie Bromley BSc (Hons), PhD
General Manager and Managing Director, United Kingdom & Ireland
Biogen